Epstein-Barr virus-associated post-transplant lymphoproliferative disorder presenting with skin involvement after CD34-selected autologous peripheral blood stem cell transplantation

European Journal of Dermatology

Volumn 17, Issue 3, 2007, Pages 242-244

  Takahashi, Sanae ^a   Watanabe, Daisuke ^a   Miura, Kazuhisa ^a   Ozawa, Hiroaki ^a   Tamada, Yasuhiko ^a   Hara, Kazuo ^a   Matsumoto, Yoshinari ^a  

^a AICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Autologous peripheral blood stem cell transplantation; EBV; Epstein Barr virus; Hemophagocytic syndrome; Post transplant lymphoproliferative disorder; PTLD

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FERRITIN; GANCICLOVIR; HYDROXYUREA; LACTATE DEHYDROGENASE; MELPHALAN; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; B CELL LYMPHOMA; CASE REPORT; CELL STRUCTURE; COMBINATION CHEMOTHERAPY; CYTOMEGALOVIRUS INFECTION; DRUG MEGADOSE; EPSTEIN BARR VIRUS; FEMALE; FEVER; HEART FAILURE; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LUNG EDEMA; LYMPHOPROLIFERATIVE DISEASE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PANCYTOPENIA; SKIN DISEASE; SOUTHERN BLOTTING; STEM CELL TRANSPLANTATION;

ANTIGENS, CD34; EPSTEIN-BARR VIRUS INFECTIONS; FATAL OUTCOME; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; LYMPHOPROLIFERATIVE DISORDERS; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SKIN; TRANSPLANTATION, AUTOLOGOUS;

EID: 34249796962     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: 10.1684/ejd.2007.0158     Document Type: Article

References (14)

1. Loren AW, Porter DL, Stadtmauer EA, Tsai DE. Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant 2003; 31: 145-55.
2. Harris NL, Swerdlow SH, Frizzera G, Knowles DM. Post-transplant lymphoproliferative disorders. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001: 264-9.
3. Beynet DP, Wee SA, Horwitz SS, et al. Clinical and pathological features of posttransplantation lymphoproliferative disorders presenting with skin involvement in 4 patients. Arch Dermatol 2004; 140: 1140-6.
4. Blokx WA, Andriessen MP, van Hamersvelt HW, van Krieken JH. Initial spontaneous remission of posttransplantation Epstein Barr virus-related B-cell lymphoproliferative disorder of the skin in a renal transplant recipient: case report and review of the literature on cutaneous B-cell posttransplantation lymphoproliferative disease. Am J Dermatopathol 2002; 24: 414-22.
5. Peniket AJ, Perry AR, Williams CD, et al. A case of EBV-associated lymphoproliferative disease following high-dose therapy and CD34-purified autologous peripheral blood progenitor cell transplantation. Bone Marrow Transplant 1998; 22: 307-9.
6. Powell JL, Bunin NJ, Callahan C, et al. An unexpectedly high incidence of Epstein-Barr virus lymphoproliferative disease after CD34+ selected autologous peripheral blood stem cell transplant in neuroblastoma. Bone Marrow Transplant 2004; 33: 651-7.
7. Nash RA, Dansey R, Storek J, et al. Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Biol Blood Marrow Transplant 2003; 9: 583-91.
8. Jenkins D, DiFrancesco L, Chaudhry A, et al. Successful treatment of post-transplant lymphoproliferative disorder in autologous blood stem cell transplant recipients. Bone Marrow Transplant 2002; 30: 321-6.
9. Blaes AH, Peterson BA, Bartlett N, et al. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Cancer 2005; 104: 1661-7.
10. Pakakasama S, Eames GM, Morriss MC, et al. Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes. Transplantation 2004; 78: 755-7.
11. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplant lymphoproliferative disorders: results of a prospective multicentre phase II study. Blood 2006; 107: 3053-7.
12. Larroche C, Mouthon L. Pathogenesis of hemophagocytic syndrome (HPS). Autoimmun Rev 2004; 3: 69-75.
13. Wang IJ, Lu MY, Chiang BL, et al. Epstein-Barr virus associated post-transplantation lymphoproliferative disorder with hemophagocytosis in a child with Wiskott-Aldrich syndrome. Pediatr Blood Cancer 2005; 45: 340-3.
14. George TI, Jeng M, Berquist W, et al. Epstein-Barr virus-associated peripheral T-cell lymphoma and hemophagocytic syndrome arising after liver transplantation: case report and review of the literature. Pediatr Blood Cancer 2005; 44: 270-6.